Common Contracts
11 similar Proceeds Agreement contracts by Baker Bros. Advisors Lp
PROCEEDS AGREEMENTProceeds Agreement • May 24th, 2023 • Baker Bros. Advisors Lp • Pharmaceutical preparations
WHEREAS, the Agent, in his capacity as a director of ACADIA Pharmaceuticals Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 12,500 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 3rd, 2023 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances)
WHEREAS, the Agent, in his capacity as a director of Seagen Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,750 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • January 17th, 2023 • Baker Bros. Advisors Lp • Pharmaceutical preparations
AGREEMENT dated as of January 12, 2023 by and between Baker Bros. Advisors LP (the “Management Company”) and Dr. Stephen Biggar (the “Agent”).
PROCEEDS AGREEMENTProceeds Agreement • May 18th, 2021 • Baker Bros. Advisors Lp • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 18th, 2021 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seagen Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 17,500 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • April 24th, 2020 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 17,500 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 1st, 2019 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 10,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • February 27th, 2019 • Baker Bros. Advisors Lp • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 2nd, 2018 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 10,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • May 17th, 2017 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 10,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • March 8th, 2016 • Baker Bros. Advisors Lp • Biological products, (no disgnostic substances) • New York
WHEREAS, the Agent, in his capacity as a director of Seattle Genetics, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 10,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
